House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar. The bill calls for a “temporary increase in Medicare Part B payments for certain biosimilars,” […]
House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar. The bill calls for a “temporary increase in Medicare Part B payments for certain biosimilars,” […]
ASBM Welcomes Ralph McKibbin, MD as Chairman In a Full Member Call September 9th, ASBM introduced gastroenterologist Ralph McKibbin, MD, FACP, FACG, AGAF as the organization’s incoming chairman. Dr. McKibbin began his three year term on September 1st, succeeding outgoing chair Madelaine Feldman, MD, FACR. Dr. McKibbin is the fourth chairman since ASBM was […]
ASBM Welcomes Ralph McKibbin, MD as Chairman In a Full Member Call September 9th, ASBM introduced gastroenterologist Ralph McKibbin, MD, FACP, FACG, AGAF as the organization’s incoming chairman. Dr. McKibbin began his three year term on September 1st, succeeding outgoing chair Madelaine Feldman, MD, FACR. Dr. McKibbin is the fourth chairman since ASBM was […]
Madelaine Feldman Completes Term as ASBM Chair On August 31st, ASBM Chair Madelaine Feldman, MD, FACR completed her term as ASBM Chair. ASBM Executive Director Michael Reilly praised Dr. Feldman’s leadership: Dr. Feldman led ASBM during a difficult time, keeping ASBM engaged on important biosimilar policy issues during the COVID-19 pandemic. As […]
Minnesota Budget Passes Without Biosimilar Provisions On June 29th, Minnesota Governor Tim Walz signed his state’s HHS Omnibus budget for 2022-2023. The legislature had considered but ultimately rejected language aimed at boosting uptake of biosimilars – provisions which many patient groups believed might inadvertently increase out-of-pocket costs. Since April, ASBM and other organizations including […]
ASBM Launches Online Biosimilars Course for Pharmacists ASBM, in conjunction with the Long Island University College of Pharmacy (LIU-Pharmacy), is now offering a comprehensive continuing education course on biosimilars entitled “Biosimilars: What Pharmacists Need to Know”. The course is accredited by the American Council on Pharmaceutical Education (ACPE), meaning course credit is available to […]
ASBM Launches Online Biosimilars Course for Pharmacists ASBM, in conjunction with the Long Island University College of Pharmacy (LIU-Pharmacy), is now offering a comprehensive continuing education course on biosimilars entitled “Biosimilars: What Pharmacists Need to Know”. The course is accredited by the American Council on Pharmaceutical Education (ACPE), meaning course credit is available to […]
Oklahoma Becomes Final State to Permit Biosimilar Substitution On April 22nd, Oklahoma Governor Kevin Stitt signed SB 4, making Oklahoma the 50th and final state to enact a law permitting biosimilar substitution. SB 4, like similar legislation in other states, permits interchangeable biosimilars to be substituted at the pharmacy level once approved by […]
ASBM Leads Three Panel Discussions at Festival of Biologics USA 2021 From March 29th-31st ASBM representatives led three panel discussions at the World Biosimilar Congress USA 2021, part of the annual Festival of Biologics USA. Typically held in San Diego, CA, the event was conducted virtually this year due the COVID-19 pandemic. On March 29th, […]
